Kunduraci M, Kirik F, Onur I, Onur O, Karsidag C, Yigit F
Eye (Lond). 2024; 39(1):94-101.
PMID: 39375488
PMC: 11733284.
DOI: 10.1038/s41433-024-03381-x.
Stasiewicz A, Conde T, Domingues M, Domingues P, Biernacki M, Skrzydlewska E
Antioxidants (Basel). 2024; 13(3).
PMID: 38539810
PMC: 10967502.
DOI: 10.3390/antiox13030276.
Wu Y, Han C, Luo R, Cai W, Xia Q, Jiang R
Front Mol Neurosci. 2024; 16:1331438.
PMID: 38188196
PMC: 10771850.
DOI: 10.3389/fnmol.2023.1331438.
Hashiesh H, Sheikh A, Nagoor Meeran M, Saraswathiamma D, Jha N, Sadek B
ACS Pharmacol Transl Sci. 2023; 6(8):1129-1142.
PMID: 37588762
PMC: 10425997.
DOI: 10.1021/acsptsci.3c00027.
Mugnaini C, Kostrzewa M, Casini M, Kumar P, Catallo V, Allara M
Molecules. 2023; 28(13).
PMID: 37446625
PMC: 10343475.
DOI: 10.3390/molecules28134958.
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.
Maccarrone M, Di Marzo V, Gertsch J, Grether U, Howlett A, Hua T
Pharmacol Rev. 2023; 75(5):885-958.
PMID: 37164640
PMC: 10441647.
DOI: 10.1124/pharmrev.122.000600.
Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential.
Vuic B, Milos T, Tudor L, Konjevod M, Nikolac Perkovic M, Jazvinscak Jembrek M
Biomedicines. 2022; 10(12).
PMID: 36551756
PMC: 9775106.
DOI: 10.3390/biomedicines10123000.
Polyfluoroalkylated antipyrines in Pd-catalyzed transformations.
Shchegolkov E, Burgart Y, Matsneva D, Borisevich S, Kadyrova R, Orshanskaya I
RSC Adv. 2022; 11(56):35174-35181.
PMID: 35493195
PMC: 9042801.
DOI: 10.1039/d1ra06967e.
Cannabis for Rheumatic Disease Pain: a Review of Current Literature.
Nowell W, Gavigan K, Silverman S
Curr Rheumatol Rep. 2022; 24(5):119-131.
PMID: 35486218
DOI: 10.1007/s11926-022-01065-7.
Cannabinoids in rheumatology: Friend, foe or a bystander?.
Jain N, Moorthy A
Musculoskeletal Care. 2022; 20(2):416-428.
PMID: 35476898
PMC: 9322323.
DOI: 10.1002/msc.1636.
A critical review of cannabis in medicine and dentistry: A look back and the path forward.
Abidi A, Alghamdi S, Derefinko K
Clin Exp Dent Res. 2022; 8(3):613-631.
PMID: 35362240
PMC: 9209799.
DOI: 10.1002/cre2.564.
Characterization of hypotensive and vasorelaxant effects of PHAR-DBH-Me a new cannabinoid receptor agonist.
Lopez-Canales O, Pavon N, Ubaldo-Reyes L, Juarez-Oropeza M, Torres-Duran P, Regla I
Korean J Physiol Pharmacol. 2022; 26(2):77-86.
PMID: 35203058
PMC: 8890940.
DOI: 10.4196/kjpp.2022.26.2.77.
Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist.
Hashiesh H, Sharma C, Goyal S, Jha N, Ojha S
Front Pharmacol. 2021; 12:702675.
PMID: 34393784
PMC: 8363263.
DOI: 10.3389/fphar.2021.702675.
Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma.
Vallee A, Lecarpentier Y, Vallee J
Int J Mol Sci. 2021; 22(7).
PMID: 33917605
PMC: 8038773.
DOI: 10.3390/ijms22073798.
Mini-review: The therapeutic role of cannabinoids in neuroHIV.
Yadav-Samudrala B, Fitting S
Neurosci Lett. 2021; 750:135717.
PMID: 33587986
PMC: 7994193.
DOI: 10.1016/j.neulet.2021.135717.
Cannabinoids in Glaucoma Patients: The Never-Ending Story.
Passani A, Posarelli C, Sframeli A, Perciballi L, Pellegrini M, Guidi G
J Clin Med. 2020; 9(12).
PMID: 33302608
PMC: 7763320.
DOI: 10.3390/jcm9123978.
Molecular Mechanism and Cannabinoid Pharmacology.
Schurman L, Lu D, Kendall D, Howlett A, Lichtman A
Handb Exp Pharmacol. 2020; 258:323-353.
PMID: 32236882
PMC: 8637936.
DOI: 10.1007/164_2019_298.
Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Sachdev S, Banister S, Santiago M, Bladen C, Kassiou M, Connor M
Pharmacol Res Perspect. 2020; 8(2):e00566.
PMID: 32101383
PMC: 7043210.
DOI: 10.1002/prp2.566.
Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers.
Bian Y, Jing Y, Wang L, Ma S, Jun J, Xie X
Mol Pharm. 2019; 16(6):2605-2615.
PMID: 31013097
PMC: 6732211.
DOI: 10.1021/acs.molpharmaceut.9b00182.
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1)-one-3-carboxamide scaffold.
Cooper A, Oyagawa C, Manning J, Singh S, Hook S, Grimsey N
Medchemcomm. 2019; 9(12):2055-2067.
PMID: 30647881
PMC: 6301273.
DOI: 10.1039/c8md00448j.
